{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2013"],"condition":["liver only metastasis from KRAS Exon 2 wild type (under protocol 1.0-1.2 edition) and RAS wild type (under protocol 2.0 edition) colorectal cancer","Neoplasm Metastasis","Neoplasms, Second Primary","Colorectal Cancer","Liver Metastasis","Colorectal Neoplasms"],"disease":["Neoplasm Metastasis","Neoplasms, Second Primary","Liver Only Metastasis From Kras Exon 2 Wild Type (under Protocol 1.0-1.2 Edition) And Ras Wild Type (under Protocol 2.0 Edition) Colorectal Cancer","Colorectal Cancer","Liver Metastasis","Colorectal Neoplasms"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2143313"],"location":["Japan"],"study_start_month":["5"],"keyword":["Oxaliplatin","Liver only metastasis from KRAS Exon 2 wild type","Cetuximab","Liver only metastasis from RAS wild type","Fluorouracil","Bevacizumab"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"Exploratory Study in Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases","description":"The correlation between the values of angiogenesis-related growth factors in plasma and efficacy, and biomarkers relevant as prognostic factors or predictive factors for sensitivity or resistance to treatment will be examined exploratively.","dates":{"creation":"2013-05-15"},"accession":"2143313","cross_references":{"University Hospital Medical Information Network CTR":["UMIN000010429"],"ClinicalTrials___gov":["NCT01834014"],"Japan Primary Registries Network":["JPRN-UMIN000010429"]}}